Immix Biopharma, Inc. (IMMX) Reports 89% CR in NEXICART-2; MRD May Lift to 98%

Immix Biopharma reported an 89% complete response rate (40/45) in an interim NEXICART-2 update. Four MRD-negative pending patients may lift CR up to 98% (44/45). No relapses or neurotoxicity observed to-date; final readout and BLA submission planned in 2027.Material DetailsContext by AI AnalystThis…